Thornburg Investment Management Inc. Trims Position in Insmed, Inc. $INSM

Posted by Brenda Bartman on Jun 15th, 2026

Thornburg Investment Management Inc. cut its holdings in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) by 13.8% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 37,971 shares of the biopharmaceutical company’s stock after selling 6,077 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Insmed were worth $6,608,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. Kingsview Wealth Management LLC grew its stake in Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 60 shares during the period. Choreo LLC grew its stake in Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 65 shares during the period. EverSource Wealth Advisors LLC grew its stake in Insmed by 10.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after purchasing an additional 69 shares during the period. Finally, ORG Partners LLC grew its stake in Insmed by 12.7% in the fourth quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 74 shares during the period.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on INSM shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Insmed in a research note on Wednesday. Truist Financial reduced their price target on Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Jefferies Financial Group started coverage on Insmed in a research note on Monday, March 16th. They issued a “buy” rating and a $228.00 price target on the stock. Raymond James Financial started coverage on Insmed in a research note on Friday, April 10th. They issued an “outperform” rating and a $200.00 price target on the stock. Finally, Leerink Partners upped their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 24th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $212.50.

View Our Latest Stock Report on INSM

Insmed Stock Performance

NASDAQ INSM opened at $97.85 on Monday. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The stock has a market cap of $21.21 billion, a P/E ratio of -17.02 and a beta of 0.79. The stock’s fifty day moving average price is $124.55 and its 200-day moving average price is $150.91. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80.

Insmed (NASDAQ:INSM – Get Free Report) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The firm had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. During the same period in the prior year, the firm posted ($1.42) earnings per share. The company’s quarterly revenue was up 229.7% on a year-over-year basis. As a group, equities analysts forecast that Insmed, Inc. will post -2.54 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO William Lewis sold 7,605 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $777,763.35. Following the sale, the chief executive officer directly owned 265,432 shares of the company’s stock, valued at approximately $27,145,730.64. This represents a 2.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Roger Adsett sold 2,370 shares of the stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $102.27, for a total value of $242,379.90. Following the completion of the sale, the chief operating officer directly owned 98,603 shares in the company, valued at approximately $10,084,128.81. This represents a 2.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 160,482 shares of company stock valued at $24,438,193. Insiders own 2.10% of the company’s stock.

Insmed Company Profile

(Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.